MarketPeel
Insider Trading Intelligence
Pricing
…
DM

Derek M. Meisner

XFOR
CHIEF LEGAL OFFICER · X4 PHARMACEUTICALS, INC · CIK 0001752461
FILING MIX · LIFETIME38%/62%
BUYS
19
SELLS
31
TOTAL VALUE
$531.4K
COMPANIES
2
ACTIVE SINCE
Aug 2020
HOLDINGS NOW
319,154
AVG SELL PX
$2.91
TRADE KIND
SHOWING 50 / 50
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
27 backtested trades · 8 horizons · 49 pending
Forward-return performance of every backtestable P/S trade by Derek M. Meisner, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d27+59.26%+0.84%-0.15%+0.99%-2.62%—
14d27+59.26%-1.55%-0.70%-0.85%-3.04%—
30d27+37.04%+9.29%-0.30%+9.59%+16.85%—
60d27+37.04%+24.14%-0.68%+24.81%+18.98%—
90d27+44.44%+9.65%-0.95%+13.53%+32.06%—
180d27(15 pending)+83.33%-25.96%+5.95%-31.91%-28.42%—
1y27(16 pending)+54.55%-16.32%+9.42%-25.75%-31.96%—
2y27(18 pending)+100.00%-48.91%+25.55%-74.46%-76.93%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
XFOR · 145,155 shares · as of Aug 17, 2022
040,45580,911121,366161,82120212022SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 19 buys / 31 sellsCOVERAGE · 23 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
Chief Legal Officer & Corp Sec
2,090$1.85$3.9K176,089Mar 6, 2026Mar 10, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
2,090——71,048Mar 6, 2026Mar 10, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,090$3.26$6.8K173,999Mar 6, 2026Mar 10, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
Chief Legal Officer & Corp Sec
9,406$1.85$17.4K183,405Feb 27, 2026Mar 3, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
9,406——73,138Feb 27, 2026Mar 3, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
9,406$3.01$28.3K173,999Feb 27, 2026Mar 3, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
Chief Legal Officer & Corp Sec
2,671$1.85$4.9K176,670Jan 28, 2026Jan 28, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,671$3.00$8.0K173,999Jan 28, 2026Jan 28, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
2,671——82,544Jan 28, 2026Jan 28, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
15,085$3.00$45.3K173,999Jan 26, 2026Jan 28, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
15,085——85,215Jan 26, 2026Jan 28, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
Chief Legal Officer & Corp Sec
15,085$1.85$27.9K189,084Jan 26, 2026Jan 28, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
5,633$1.90$10.7K173,999Jan 23, 2026Jan 23, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
1,054$1.84$1.9K179,632Jan 22, 2026Jan 23, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
2,247$1.81$4.1K180,686Jan 21, 2026Jan 23, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
99,133——182,933Jan 16, 2026Jan 21, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
148,700——148,700Jan 16, 2026Jan 21, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
8,548$1.71$14.7K83,800Jan 12, 2026Jan 12, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
5,200$1.76$9.2K92,348Jan 9, 2026Jan 12, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
6,819$1.82$12.4K127,640Jan 8, 2026Jan 12, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
30,092$1.82$54.9K97,548Jan 8, 2026Jan 12, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
10,070$1.99$20.0K134,459Jan 7, 2026Jan 7, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
1,700$1.99$3.4K144,529Jan 7, 2026Jan 7, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
3,801$1.97$7.5K146,229Jan 6, 2026Jan 7, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
7,097$1.97$14.0K150,030Jan 6, 2026Jan 7, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
Chief Legal Officer & Corp Sec
4,000$1.96$7.8K157,127Jan 5, 2026Jan 7, 2026 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
3,418$1.59$5.4K161,127Jan 21, 2025Jan 23, 2025 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
66,800——164,545Jan 6, 2025Jan 7, 2025 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
100,300——100,300Jan 6, 2025Jan 7, 2025 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,122$1.84$20.5K97,745Jan 3, 2025Jan 7, 2025 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
8,933$3.48$31.0K108,867Jan 19, 2024Jan 19, 2024 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
137,000——137,000Jan 2, 2024Jan 4, 2024 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
91,000——117,800Jan 2, 2024Jan 4, 2024 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
26,800——26,800Jan 17, 2023Jan 18, 2023 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
120,800——120,800Jan 17, 2023Jan 18, 2023 ↗View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
225,000——225,000Sep 6, 2022Sep 7, 2022 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Legal Officer
8,334——145,155Aug 17, 2022Aug 19, 2022 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Legal Officer
4,166——153,489Jun 24, 2022Jun 27, 2022 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Legal Officer
4,166——157,655Jun 16, 2022Jun 17, 2022 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
105,000——161,821Mar 1, 2022Mar 1, 2022 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Legal Officer
15,909——56,821Feb 11, 2022Feb 14, 2022 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
General Counsel
8,332$5.10$42.5K72,730Aug 17, 2021Aug 19, 2021 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
General Counsel
4,166$7.00$29.2K81,062Jun 24, 2021Jun 25, 2021 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
12,500——85,228Jun 23, 2021Jun 25, 2021 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
12,500——76,894Jun 15, 2021Jun 17, 2021 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
General Counsel
4,166$7.84$32.7K72,728Jun 15, 2021Jun 17, 2021 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
47,728——64,394Mar 24, 2021Mar 25, 2021 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
General Counsel
8,334$8.05$67.1K16,666Sep 9, 2020Sep 10, 2020 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
12,500——25,000Aug 17, 2020Aug 18, 2020 ↗View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
12,500——12,500Aug 14, 2020Aug 18, 2020 ↗View →
Other insiders · XFOR
Loading peer insiders…
About this filer
CIK 0001752461
ROLE
Chief Legal Officer
PRIMARY
XFOR
COMPANIES
2
ACTIVE SINCE
Aug 2020
MARKETPEEL · /INSIDER/0001752461DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback